PASK and metabolic dysfunction-associated steatotic liver disease: To a large extent, PASK-/- could be successfully protected from obesity, implying that PASK may participate in lipogenesis and metabolism and therefore may be a new therapeutic target for the treatment of metabolic diseases and disorders such as NAFLD.